Vir Biotechnology (VIR) announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the combination of tobevibart and elebsiran to continued bulevirtide monotherapy in participants with chronic hepatitis delta who have not achieved undetectable hepatitis delta virus RNA despite bulevirtide treatment. ECLIPSE 2 is one of three trials in Vir Biotechnology’s registrational ECLIPSE program for CHD, which was initiated in March 2025. ECLIPSE 2 is designed to provide the registrational efficacy and safety data needed for potential submission to global regulatory agencies, including agencies in the U.S. and Europe.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology Begins Phase 1 Trial for VIR-5525
- Vir Biotechnology doses first patient in VIR-5525 trial
- Insider Moves: Fastenal, Vir, Cipher, Verisign, HEICO
- CoreWeave initiated, Texas Instruments upgraded: Wall Street’s top analyst calls
- Vir Biotechnology initiated with an Outperform at Raymond James